MTOR and neoplasm: Specifically, in a genetic model of papillary renal cancer triggered by Tsc2 heterozygous inactivation, Pml genetic deletion accelerated tumor progression, and this was accompanied by increased mTOR activity in the kidney (Bernardi et al, 2011).